论文部分内容阅读
2010年美国癌症学会公布了美国癌症的最新统计数据,男性膀胱癌的发病率占全身肿瘤的7%,居第四位,死亡率占全身肿瘤的3%,居第九位;女性膀胱癌的发病率占全身肿瘤的2.4%,死亡率占全身肿瘤的1.58%。而在我国,膀胱癌是泌尿外科最常见的肿瘤,占全部恶性肿瘤的3.2%。在新发现的膀胱癌中,约40%分化不良,就诊时可能半数已经浸润至肌肉层,并有潜在隐性转移病灶,一旦发生转移,多数在2年内死亡。因此研究抗膀胱癌的药物
2010 American Cancer Society released the latest statistics of cancer in the United States, the incidence of bladder cancer in men accounts for 7% of systemic tumors, ranking fourth, the mortality rate of 3% of systemic tumors, ranking ninth; bladder cancer in women The incidence of systemic tumors accounted for 2.4%, the mortality rate of 1.58% of systemic tumors. In our country, bladder cancer is the most common urological tumor, accounting for 3.2% of all malignant tumors. About 40% of newly diagnosed bladder cancers are poorly differentiated and may have infiltrated the muscular layer at the time of diagnosis and have potentially occult metastatic lesions, most of whom die within 2 years after metastasis. Therefore, the study of anti-bladder cancer drugs